Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Michael Seminerio"'
Autor:
Michel Lanteri-Minet, Elizabeth Leroux, Zaza Katsarava, Richard B. Lipton, Fumihiko Sakai, Manjit Matharu, Kristina Fanning, Aubrey Manack Adams, Katherine Sommer, Michael Seminerio, Dawn C. Buse
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Objective To assess rates of traversing barriers to care to access optimal clinical outcomes in people with migraine internationally. Background People in need of medical care for migraine should consult a health care professional knowledgea
Externí odkaz:
https://doaj.org/article/35d3951a2ed94226982c1beef0ccd5ab
Autor:
Maurice T. Driessen, Joshua M. Cohen, Oscar Patterson-Lomba, Stephen F. Thompson, Michael Seminerio, Karen Carr, Todor I. Totev, Rochelle Sun, Erica Yim, Fan Mu, Rajeev Ayyagari
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-15 (2022)
Abstract Background The efficacy and tolerability of fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP) and is approved for the preventive treatment of migraine in adults, hav
Externí odkaz:
https://doaj.org/article/12dd913a8637410284ba9557236c8ce7
Autor:
Stephen D. Silberstein, Shoshana Reshef, Joshua M. Cohen, Sanjay Gandhi, Michael Seminerio, Verena Ramirez Campos, Yoel Kessler, Stephen F. Thompson, Andrew Blumenfeld
Publikováno v:
Advances in Therapy. 40:445-459
Through 2018, three calcitonin gene-related peptide pathway-targeted monoclonal antibodies (CGRP mAbs) had received US Food and Drug Administration (FDA) approval for migraine prevention: erenumab, fremanezumab, and galcanezumab.This retrospective an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::727d63d4d6216987d538e73b8d27cb05
https://doi.org/10.1007/s12325-022-02346-4
https://doi.org/10.1007/s12325-022-02346-4
Autor:
Sebastiano, Intagliata, Walid F, Alsharif, Christophe, Mesangeau, Nicola, Fazio, Michael, Seminerio, Yan-Tong, Xu, Rae R, Matsumoto, Christopher R, McCurdy
Publikováno v:
European journal of medicinal chemistry. 165
Sigma receptors (σRs) are considered to be a significant and valid target for developing new medications to address several diseases. Their potential involvement in numerous central nervous system disorders, neuropathic pain, addiction, and cancer h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a3ad701ba3e0f20b70d18c1bcc8ab9ed
https://pubmed.ncbi.nlm.nih.gov/30685525
https://pubmed.ncbi.nlm.nih.gov/30685525